Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial.

doi:10.1182/blood.2020005998

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial.

Blood - 24 Dec 2020

Kapp-Schwoerer Silke, Weber Daniela, Corbacioglu Andrea, Gaidzik Verena I, Paschka Peter, Krönke Jan, Theis Frauke, Rücker Frank G, Teleanu Maria-Veronica, Panina Ekaterina, Jahn Nikolaus, Herzig Julia, Kubanek Lena, Schrade Anika, Göhring Gudrun, Fiedler Walter, Kindler Thomas, Schroeder Thomas, Mayer Karin T, Lübbert Michael, Wattad Mohammed, Götze Katharina S, Horst Heinz A, Koller Elisabeth, Wulf Gerald, Schleicher Jan, Bentz Martin, Krauter Jürgen, Bullinger Lars, Krzykalla Julia, Benner Axel, Schlenk Richard F, Thol Felicitas, Heuser Michael, Ganser Arnold, Döhner Hartmut, Döhner Konstanze

Abstract excerpt

Monitoring of measurable residual disease (MRD) provides prognostic information in patients with Nucleophosmin1-mutated (NPM1mut) acute myeloid leukemia (AML) and represents a powerful tool to evaluate treatment effects within clinical trials. We determined NPM1mut transcript levels (TLs) by quantitative reverse-transcription polymerase chain reaction and evaluated the prognostic impact of NPM1mut MRD and the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bone Marrow

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease-Free Survival

Share to Leukemia, Myeloid, Acute

Share to Neoplasm Proteins

Share to Neoplasm, Residual

Share to Nucleophosmin

Share to Recurrence

Share to Survival Rate

Source

Open in PubMed

Identifiers

PMID: 33367545
DOI: 10.1182/blood.2020005998

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial.PMID 33367545Read ↗

Real-World Outcomes in NPM1-Mutated Acute Myeloid Leukemia: The Impact of Measurable Residual Disease on Disease Relapse.Semantic proximity Read ↗

Gemtuzumab Ozogamicin in NPM1-Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study.Semantic proximity Read ↗

MRD assessed byWT1andNPM1transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicinSemantic proximity Read ↗

Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML.Semantic proximity Read ↗

Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group.Semantic proximity Read ↗

Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML.Semantic proximity Read ↗

Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML.Semantic proximity Read ↗

Molecular measurable residual disease monitoring and transplant indications in NPM1 mutated acute myeloid leukemia.Semantic proximity Read ↗

Monitoring of minimal residual disease in acute myeloid leukemia with frequent and rare patient-specific NPM1 mutations.Semantic proximity Read ↗

Minimal residual disease detection in acute myeloid leukemia by mutant nucleophosmin (NPM1): comparison with WT1 gene expression.Semantic proximity Read ↗

The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AMLSemantic proximity Read ↗

High NPM1 mutant allele burden at diagnosis correlates with minimal residual disease at first remission in de novo acute myeloid leukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.